

R Michael Tuttle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2346573/publications.pdf>

Version: 2024-02-01

213
papers

36,356
citations

13854

67
h-index

3321

184
g-index

234
all docs

234
docs citations

234
times ranked

14879
citing authors

#	ARTICLE	IF	CITATIONS
1	Nuances in the Surgical Management of Thyroid Cancer. Indian Journal of Surgical Oncology, 2022, 13, 1-6.	0.3	0
2	Does macroscopic extrathyroidal extension to the strap muscles alone affect survival in papillary thyroid carcinoma?. Surgery, 2022, 171, 1341-1347.	1.0	5
3	Invasion of a Recurrent Laryngeal Nerve from Small Well-Differentiated Papillary Thyroid Cancers: Patient Selection Implications for Active Surveillance. Thyroid, 2022, 32, 164-169.	2.4	12
4	Enhancing Radioiodine Incorporation in <i>BRAF</i> -Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial. Thyroid, 2022, 32, 273-282.	2.4	30
5	Follicular and Hurthle Cell Carcinoma: Comparison of Clinicopathological Features and Clinical Outcomes. Thyroid, 2022, 32, 245-254.	2.4	17
6	Surgical Management of Low-/Intermediate-Risk Node Negative Thyroid Cancer: A Single-Institution Study Using Propensity Matching Analysis to Compare Thyroid Lobectomy and Total Thyroidectomy. Thyroid, 2022, 32, 28-36.	2.4	19
7	Letter to the Editor From Boucai and Tuttle: <i>BRAF</i> V600E Status Sharply Differentiates Lymph Node Metastasis-Associated Mortality Risk in Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2022, , .	1.8	1
8	American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment. Head and Neck, 2022, 44, 1277-1300.	0.9	41
9	Practice patterns in the management of thyroid cancer. Journal of Surgical Oncology, 2022, 126, 214-216.	0.8	0
10	Radiofrequency ablation and related <i>ultrasound</i> -guided ablation technologies for treatment of benign and malignant thyroid disease: An international multidisciplinary consensus statement of the American Head and Neck Society Endocrine Surgery Section with the Asia Pacific Society of Thyroid Surgery, Associazione Medici Endocrinologi, British Association of Endocrine and Thyroid Surgeons, European Thyroid Association, Italian Society of Endocrine Surgery Units, Korean Society of Thyroid Radiology. Head and Neck, 2022, 44, 633-660.	0.9	92
11	Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA). Journal of Clinical Oncology, 2022, 40, 1870-1878.	0.8	29
12	The solid variant of papillary thyroid carcinoma: a multi-institutional retrospective study. Histopathology, 2022, 81, 171-182.	1.6	9
13	Frozen section of central lymph nodes in thyroid cancer. Gland Surgery, 2022, 11, 637-639.	0.5	2
14	A Pilot Study of Durvalumab (MEDI4736) with Tremelimumab in Combination with Image-Guided Stereotactic Body Radiotherapy in the Treatment of Metastatic Anaplastic Thyroid Cancer. Thyroid, 2022, 32, 799-806.	2.4	4
15	Radioactive iodine therapy: multiple faces of the same polyhedron. Archives of Endocrinology and Metabolism, 2022, , .	0.3	2
16	Outcomes and Toxicities of Nonmedullary Thyroid Tumors Treated with Proton Beam Radiation Therapy. International Journal of Particle Therapy, 2022, 9, 20-30.	0.9	0
17	Is a Prophylactic Central Compartment Neck Dissection Required in Papillary Thyroid Carcinoma Patients with Clinically Involved Lateral Compartment Lymph Nodes?. Annals of Surgical Oncology, 2021, 28, 512-518.	0.7	15
18	Data set for reporting carcinoma of the thyroid: recommendations from the International Collaboration on Cancer Reporting. Human Pathology, 2021, 110, 62-72.	1.1	20

#	ARTICLE	IF	CITATIONS
19	Perioperative diagnostics of patients referred for radioiodine therapy of differentiated thyroid carcinoma: referral center experience in an iodine-insufficient country. <i>Endocrine</i> , 2021, 72, 721-726.	1.1	3
20	Commentary: Re-recurrence after surgical management of recurrent thyroid cancer. <i>Surgery</i> , 2021, 169, 844-845.	1.0	0
21	Completion thyroidectomyâ€”Have we made appropriate decisions?. <i>Journal of Surgical Oncology</i> , 2021, 123, 37-38.	0.8	3
22	How Does The AJCC/TNM Staging System Eighth Edition Perform in Thyroid Cancer at A Major Middle Eastern Medical Center?. <i>Endocrine Practice</i> , 2021, 27, 607-613.	1.1	8
23	Frequent neck US in papillary thyroid cancer likely detects nonâ€”actionable findings. <i>Clinical Endocrinology</i> , 2021, 94, 504-512.	1.2	4
24	Papillary Carcinoma Observation. , 2021, , 199-203.e1.		0
25	Delphian nodeâ€”A sentinel node in thyroid cancer?. <i>Journal of Surgical Oncology</i> , 2021, 123, 1529-1530.	0.8	1
26	Prophylactic Lateral Neck Dissection for Medullary Thyroid Carcinoma is not Associated with Improved Survival. <i>Annals of Surgical Oncology</i> , 2021, 28, 6572-6579.	0.7	18
27	Management of the contralateral central neck in differentiated thyroid cancer: A contentious issue. <i>European Journal of Surgical Oncology</i> , 2021, 47, 717-719.	0.5	0
28	Patient Perspectives on the Extent of Surgery and Radioactive Iodine Treatment for Low-Risk Differentiated Thyroid Cancer. <i>Endocrine Practice</i> , 2021, 27, 383-389.	1.1	6
29	Ultrasound-Guided Percutaneous Laser Ablation of the Thyroid Gland in a Swine Model: Comparison of Ablation Parameters and Ablation Zone Dimensions.. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 1798-1806.	0.9	4
30	A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, the Society of Nuclear Medicine and Molecular Imaging on Current Diagnostic and Theranostic Approaches in the Management of Thyroid Cancer. <i>Thyroid</i> , 2021, 31, 1009-1019.	2.4	54
31	Intensityâ€”modulated radiation therapy and doxorubicin in thyroid cancer: A prospective phase 2 trial. <i>Cancer</i> , 2021, 127, 4161-4170.	2.0	8
32	Dynamic Risk Group Analysis and Staging for Differentiated Thyroid Cancer. , 2021, , 218-224.e1.		0
33	Papillary microcarcinomaâ€”Management issues. <i>Indian Journal of Cancer</i> , 2021, 58, 155.	0.2	0
34	Should multifocality be an indication for completion thyroidectomy in papillary thyroid carcinoma?. <i>Surgery</i> , 2020, 167, 10-17.	1.0	46
35	Dynamic contrastâ€”enhanced MRI model selection for predicting tumor aggressiveness in papillary thyroid cancers. <i>NMR in Biomedicine</i> , 2020, 33, e4166.	1.6	19
36	Active Surveillance in Papillary Thyroid Microcarcinomas is Feasible and Safe: Experience at a Single Italian Center. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e172-e180.	1.8	94

#	ARTICLE	IF	CITATIONS
37	Management of Retropharyngeal Lymph Node Metastases in Differentiated Thyroid Carcinoma. <i>Thyroid</i> , 2020, 30, 688-695.	2.4	14
38	Lymphovascular invasion and active surveillance in thyroid cancer. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1775-1776.	0.5	0
39	Multifocality in papillary thyroid carcinoma—An unresolved controversy. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1777-1778.	0.5	10
40	Nonsurgical Thermal Ablation of Thyroid Nodules: Not if, but Why, When, and How?. <i>Thyroid</i> , 2020, 30, 1691-1694.	2.4	12
41	ThyroidEx: Development and Preliminary Validation of a Thyroid Surgery Expectations Measure. <i>Otolaryngology - Head and Neck Surgery</i> , 2020, 165, 019459982097631.	1.1	2
42	Assessing the Number of Candidates There Are for Active Surveillance of Low-risk Papillary Thyroid Cancers in the US. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2020, 146, 585.	1.2	9
43	Structural Doubling Time Predicts Overall Survival in Patients with Medullary Thyroid Cancer in Patients with Rapidly Progressive Metastatic Medullary Thyroid Cancer Treated with Molecular Targeted Therapies. <i>Thyroid</i> , 2020, 30, 1112-1119.	2.4	15
44	Brief progress report from the intersocietal working group on differentiated thyroid cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1345-1347.	3.3	4
45	Active surveillance for patients with very low-risk thyroid cancer. <i>Laryngoscope Investigative Otolaryngology</i> , 2020, 5, 175-182.	0.6	28
46	Grading of medullary thyroid carcinoma on the basis of tumor necrosis and high mitotic rate is an independent predictor of poor outcome. <i>Modern Pathology</i> , 2020, 33, 1690-1701.	2.9	42
47	Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases. <i>Thyroid</i> , 2020, 30, 1505-1517.	2.4	143
48	How Many Papillae in Conventional Papillary Carcinoma? A Clinical Evidence-Based Pathology Study of 235 Unifocal Encapsulated Papillary Thyroid Carcinomas, with Emphasis on the Diagnosis of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. <i>Thyroid</i> , 2019, 29, 1792-1803.	2.4	33
49	Genomic and Transcriptomic Characterization of Papillary Microcarcinomas With Lateral Neck Lymph Node Metastases. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 4889-4899.	1.8	26
50	Pediatric Thyroid Cancer: A Surgical Challenge. <i>European Journal of Surgical Oncology</i> , 2019, 45, 2001-2002.	0.5	2
51	Long-Term Oncologic Outcomes After Curative Resection of Familial Medullary Thyroid Carcinoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 4423-4429.	0.7	6
52	Outcome and molecular characteristics of non-invasive encapsulated follicular variant of papillary thyroid carcinoma with oncocytic features. <i>Endocrine</i> , 2019, 64, 97-108.	1.1	35
53	Clinical Assessment and Risk Stratification in Differentiated Thyroid Cancer. <i>Endocrinology and Metabolism Clinics of North America</i> , 2019, 48, 99-108.	1.2	14
54	Risk Stratification in Differentiated Thyroid Cancer: From Detection to Final Follow-Up. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 4087-4100.	1.8	100

#	ARTICLE	IF	CITATIONS
55	Controversies, Consensus, and Collaboration in the Use of ¹³¹ I Therapy in Differentiated Thyroid Cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. <i>Thyroid</i> , 2019, 29, 461-470.	2.4	257
56	Commentary "Incidence of total thyroidectomy and lobectomy" <i>Surgery</i> , 2019, 166, 48-49.	1.0	0
57	Completion thyroidectomy-indications and complications. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1129-1131.	0.5	6
58	Ata High-Risk Thyroid Cancer Patients Demonstrating an Excellent Response to Therapy Within A Few Weeks of Initial Therapy Have Better than Expected Clinical Outcomes. <i>Endocrine Practice</i> , 2019, 25, 287-289.	1.1	4
59	Enhanced interdisciplinary communication: development of an interactive thyroid nodule/cancer disease map. <i>Laryngoscope</i> , 2019, 129, 269-274.	1.1	1
60	American Head and Neck Society Endocrine Section clinical consensus statement: North American quality statements and evidence-based multidisciplinary workflow algorithms for the evaluation and management of thyroid nodules. <i>Head and Neck</i> , 2019, 41, 843-856.	0.9	10
61	European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium. <i>Thyroid</i> , 2019, 29, 7-26.	2.4	122
62	Vemurafenib Redifferentiation of <i>BRAF</i> Mutant, RAI-Refractory Thyroid Cancers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1417-1428.	1.8	165
63	Stage migration with the new American Joint Committee on Cancer (AJCC) staging system (8th edition) for differentiated thyroid cancer. <i>Surgery</i> , 2019, 165, 6-11.	1.0	45
64	Distinguishing remnant ablation from adjuvant treatment in differentiated thyroid cancer. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 7-8.	5.5	5
65	Thyroid cancer staging and genomics. <i>Annals of Translational Medicine</i> , 2019, 7, S49-S49.	0.7	8
66	Surgical management of the recurrent laryngeal nerve in thyroidectomy: American Head and Neck Society Consensus Statement. <i>Head and Neck</i> , 2018, 40, 663-675.	0.9	58
67	A clinical framework to facilitate selection of patients with differentiated thyroid cancer for active surveillance or less aggressive initial surgical management. <i>Expert Review of Endocrinology and Metabolism</i> , 2018, 13, 77-85.	1.2	62
68	Controversial Issues in Thyroid Cancer Management. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1187-1194.	2.8	73
69	The evolving diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). <i>Human Pathology</i> , 2018, 74, 1-4.	1.1	45
70	No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial. <i>Diabetes Care</i> , 2018, 41, 620-622.	4.3	35
71	Reply: Active Surveillance in Micropapillary Carcinoma. <i>Surgery</i> , 2018, 163, 1325-1329.	1.0	0
72	Treatment decision making in early-stage papillary thyroid cancer. <i>Psycho-Oncology</i> , 2018, 27, 61-68.	1.0	44

#	ARTICLE	IF	CITATIONS
73	Differentiated and anaplastic thyroid carcinoma: Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. <i>Ca-A Cancer Journal for Clinicians</i> , 2018, 68, 55-63.	157.7	258
74	Risk Stratification in Differentiated Thyroid Cancer: Importance and Clinical Implications of Preoperative Risk Stratification. <i>VideoEndocrinology</i> , 2018, 5, .	0.1	1
75	Implementing Key Changes in The American Thyroid Association 2015 Thyroid Nodules/Differentiated Thyroid Cancer Guidelines Across Practice Types. <i>Endocrine Practice</i> , 2018, 24, 833-840.	1.1	10
76	Risk Stratification and Current Management of Low Risk Thyroid Cancer. , 2018, , 111-120.		0
77	Intensity-Modulated Radiation Therapy With or Without Concurrent Chemotherapy in Nonanaplastic Thyroid Cancer with Unresectable or Gross Residual Disease. <i>Thyroid</i> , 2018, 28, 1180-1189.	2.4	23
78	Using the American Thyroid Association Risk-Stratification System to Refine and Individualize the American Joint Committee on Cancer Eighth Edition Disease-Specific Survival Estimates in Differentiated Thyroid Cancer. <i>Thyroid</i> , 2018, 28, 1293-1300.	2.4	41
79	Thyroid Cancer Treatment Choice: A Pilot Study of a Tool to Facilitate Conversations with Patients with Papillary Microcarcinomas Considering Treatment Options. <i>Thyroid</i> , 2018, 28, 1325-1331.	2.4	42
80	Should subcentimeter non-invasive encapsulated, follicular variant of papillary thyroid carcinoma be included in the noninvasive follicular thyroid neoplasm with papillary-like nuclear features category?. <i>Endocrine</i> , 2018, 59, 143-150.	1.1	57
81	Outcome of Large Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. <i>Thyroid</i> , 2017, 27, 512-517.	2.4	109
82	Patients with Multifocal Macroscopic Papillary Thyroid Carcinoma Have a Low Risk of Recurrence at Early Follow-Up after Total Thyroidectomy and Radioactive Iodine Treatment. <i>European Thyroid Journal</i> , 2017, 6, 31-39.	1.2	10
83	Novel concepts for initiating multitargeted kinase inhibitors in radioactive iodine refractory differentiated thyroid cancer. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2017, 31, 295-305.	2.2	43
84	Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition): What Changed and Why?. <i>Thyroid</i> , 2017, 27, 751-756.	2.4	491
85	The "broken chair" in patients with differentiated thyroid cancer. <i>Endocrine</i> , 2017, 57, 359-360.	1.1	1
86	Management and outcome of clinically evident neck recurrence in patients with papillary thyroid cancer. <i>Clinical Endocrinology</i> , 2017, 87, 566-571.	1.2	15
87	Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of <i>MED12</i> and <i>RBM10</i> as Novel Thyroid Cancer Genes Associated with Tumor Virulence. <i>Clinical Cancer Research</i> , 2017, 23, 5970-5980.	3.2	89
88	Neck Sonography and Suppressed Thyroglobulin Have High Sensitivity for Identifying Recurrent/Persistent Disease in Patients With Low-Risk Thyroid Cancer Treated With Total Thyroidectomy and Radioactive Iodine Ablation, Making Stimulated Thyroglobulin Unnecessary. <i>Journal of Ultrasound in Medicine</i> , 2017, 36, 2299-2307.	0.8	8
89	Response to Letter: What Is the Role of Serum Thyroglobulin Measurement in Patients With Differentiated Thyroid Cancer Treated Without Radioactive Iodine?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2115-2116.	1.8	0
90	Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic, follicular cell-derived thyroid carcinoma. <i>Cancer</i> , 2017, 123, 2955-2964.	2.0	70

#	ARTICLE	IF	CITATIONS
91	Screening for thyroid cancer in survivors of childhood and young adult cancer treated with neck radiation. <i>Journal of Cancer Survivorship</i> , 2017, 11, 302-308.	1.5	21
92	Primary Thyroid Carcinoma with Low-Risk Histology and Distant Metastases: Clinicopathologic and Molecular Characteristics. <i>Thyroid</i> , 2017, 27, 632-640.	2.4	52
93	Natural History and Tumor Volume Kinetics of Papillary Thyroid Cancers During Active Surveillance. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017, 143, 1015.	1.2	359
94	Response to Therapy Status Is an Excellent Predictor of Pregnancy-Associated Structural Disease Progression in Patients Previously Treated for Differentiated Thyroid Cancer. <i>Thyroid</i> , 2017, 27, 396-401.	2.4	29
95	Comparison of Empiric Versus Whole-Body/-Blood Clearance Dosimetry-Based Approach to Radioactive Iodine Treatment in Patients with Metastases from Differentiated Thyroid Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 717-722.	2.8	81
96	The History of the Follicular Variant of Papillary Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 15-22.	1.8	107
97	Previous External Beam Radiation Treatment Exposure Does Not Confer Worse Outcome for Patients with Differentiated Thyroid Cancer. <i>Thyroid</i> , 2017, 27, 412-417.	2.4	5
98	Title is missing!. , 2017, , .		37
99	Pilot Study of a Web-based Decision Tool on Post-operative Use of Radioactive Iodine. <i>European Endocrinology</i> , 2017, 13, 26.	0.8	2
100	Redifferentiating Thyroid Cancer: Selumetinib-enhanced Radioiodine Uptake in Thyroid Cancer. <i>Molecular Imaging and Radionuclide Therapy</i> , 2017, 26, 80-86.	0.3	8
101	External-beam radiotherapy for differentiated thyroid cancer locoregional control: A statement of the American Head and Neck Society. <i>Head and Neck</i> , 2016, 38, 493-498.	0.9	76
102	Changing the Cancer Diagnosis: The Case of Follicular Variant of Papillary Thyroid Cancer—Primum Non Nocere and NIFTP. <i>Thyroid</i> , 2016, 26, 869-871.	2.4	48
103	Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma. <i>JAMA Oncology</i> , 2016, 2, 1023.	3.4	1,192
104	Changing Trends in the Incidence of Thyroid Cancer in the United States. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2016, 142, 709.	1.2	162
105	Challenges of Active Surveillance Protocols for Low-Risk Papillary Thyroid Microcarcinoma in the United States. <i>Thyroid</i> , 2016, 26, 989-990.	2.4	14
106	Dynamic Risk Stratification in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2692-2700.	1.8	188
107	Ethical Considerations When Counseling Patients With Thyroid Cancer About Surgery vs Observation. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2016, 142, 406.	1.2	12
108	Papillary thyroid microcarcinoma: time to shift from surgery to active surveillance?. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 933-942.	5.5	200

#	ARTICLE	IF	CITATIONS
109	Clinicopathologic Features of Fatal Non-Anaplastic Follicular Cell-Derived Thyroid Carcinomas. <i>Thyroid</i> , 2016, 26, 1588-1597.	2.4	53
110	Multi-Institutional validation of a novel textural analysis tool for preoperative stratification of suspected thyroid tumors on diffusion-weighted MRI. <i>Magnetic Resonance in Medicine</i> , 2016, 75, 1708-1716.	1.9	50
111	Papillary thyroid microcarcinoma and active surveillance - Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 976-977.	5.5	3
112	Operative management of locally advanced, differentiated thyroid cancer. <i>Surgery</i> , 2016, 160, 738-746.	1.0	61
113	Mammary analog secretory carcinoma of the thyroid gland: A primary thyroid adenocarcinoma harboring ETV6-NTRK3 fusion. <i>Modern Pathology</i> , 2016, 29, 985-995.	2.9	74
114	Time Course and Predictors of Structural Disease Progression in Pulmonary Metastases Arising from Follicular Cell-Derived Thyroid Cancer. <i>Thyroid</i> , 2016, 26, 518-524.	2.4	41
115	An International Multi-Institutional Validation of Age 55 Years as a Cutoff for Risk Stratification in the AJCC/UICC Staging System for Well-Differentiated Thyroid Cancer. <i>Thyroid</i> , 2016, 26, 373-380.	2.4	173
116	Pediatric Differentiated Thyroid Carcinoma of Follicular Cell Origin: Prognostic Significance of Histologic Subtypes. <i>Thyroid</i> , 2016, 26, 219-226.	2.4	56
117	Effectiveness of routine ultrasonographic surveillance of patients with low-risk papillary carcinoma of the thyroid. <i>Surgery</i> , 2016, 159, 1390-1395.	1.0	14
118	A Clinical Framework to Facilitate Risk Stratification When Considering an Active Surveillance Alternative to Immediate Biopsy and Surgery in Papillary Microcarcinoma. <i>Thyroid</i> , 2016, 26, 144-149.	2.4	263
119	Management of advanced medullary thyroid cancer. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 64-71.	5.5	100
120	Defining a Valid Age Cutoff in Staging of Well-Differentiated Thyroid Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 410-415.	0.7	87
121	2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. <i>Thyroid</i> , 2016, 26, 1-133.	2.4	10,674
122	Restricting ultrasound thyroid fine needle aspiration biopsy by nodule size: which tumors are we missing? A population-based study. <i>Endocrine</i> , 2016, 51, 499-505.	1.1	6
123	A Risk-adapted Approach to Follow-up in Differentiated Thyroid Cancer. <i>Rambam Maimonides Medical Journal</i> , 2016, 7, e0004.	0.4	25
124	Serial Neck Ultrasound is More Likely to Identify False-Positive Abnormalities than Clinically Significant Disease in Low-Risk Papillary Thyroid Cancer Patients. <i>Endocrine Practice</i> , 2015, 21, 1372-1379.	1.1	38
125	Cost-effectiveness analysis of papillary thyroid cancer surveillance. <i>Cancer</i> , 2015, 121, 4132-4140.	2.0	50
126	RAI thyroid bed uptake after total thyroidectomy: A novel SPECT-CT anatomic classification system. <i>Laryngoscope</i> , 2015, 125, 2417-2424.	1.1	25

#	ARTICLE	IF	CITATIONS
127	Inappropriate Use of Radioactive Iodine for Low-Risk Papillary Thyroid Cancer Is Most Common in Regions with Poor Access to Healthcare. <i>Thyroid</i> , 2015, 25, 865-866.	2.4	7
128	Management of Recurrent/Persistent Nodal Disease in Patients with Differentiated Thyroid Cancer: A Critical Review of the Risks and Benefits of Surgical Intervention Versus Active Surveillance. <i>Thyroid</i> , 2015, 25, 15-27.	2.4	112
129	Implementing the Modified 2009 American Thyroid Association Risk Stratification System in Thyroid Cancer Patients with Low and Intermediate Risk of Recurrence. <i>Thyroid</i> , 2015, 25, 1235-1242.	2.4	36
130	Increasing diagnosis of subclinical thyroid cancers leads to spurious improvements in survival rates. <i>Cancer</i> , 2015, 121, 1793-1799.	2.0	68
131	Invasion rather than nuclear features correlates with outcome in encapsulated follicular tumors: further evidence for the reclassification of the encapsulated papillary thyroid carcinoma follicular variant. <i>Human Pathology</i> , 2015, 46, 657-664.	1.1	121
132	Using Diffusion-Weighted MRI to Predict Aggressive Histological Features in Papillary Thyroid Carcinoma: A Novel Tool for Pre-Operative Risk Stratification in Thyroid Cancer. <i>Thyroid</i> , 2015, 25, 672-680.	2.4	33
133	Lateral Neck Lymph Node Characteristics Prognostic of Outcome in Patients with Clinically Evident N1b Papillary Thyroid Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 3530-3536.	0.7	38
134	Prognostic Value of Vascular Invasion in Well-Differentiated Papillary Thyroid Carcinoma. <i>Thyroid</i> , 2015, 25, 503-508.	2.4	43
135	Frequent Screening With Serial Neck Ultrasound Is More Likely to Identify False-Positive Abnormalities Than Clinically Significant Disease in the Surveillance of Intermediate Risk Papillary Thyroid Cancer Patients Without Suspicious Findings on Follow-Up Ultrasound Evaluation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1561-1567.	1.8	34
136	Microscopic Positive Margins in Differentiated Thyroid Cancer Is Not an Independent Predictor of Local Failure. <i>Thyroid</i> , 2015, 25, 993-998.	2.4	46
137	Survival from Differentiated Thyroid Cancer: What Has Age Got to Do with It?. <i>Thyroid</i> , 2015, 25, 1106-1114.	2.4	125
138	Response to: Letter to the Editor Regarding the Article "Thyrotropin Suppression Increases the Risk of Osteoporosis Without Decreasing Recurrence in ATA Low- and Intermediate-Risk Patients with Differentiated Thyroid Carcinoma". <i>Thyroid</i> , 2015, 25, 1269-1270.	2.4	0
139	Prognostic impact of extent of vascular invasion in low-grade encapsulated follicular cell-derived thyroid carcinomas: a clinicopathologic study of 276 cases. <i>Human Pathology</i> , 2015, 46, 1789-1798.	1.1	58
140	Thyrotropin Suppression Increases the Risk of Osteoporosis Without Decreasing Recurrence in ATA Low- and Intermediate-Risk Patients with Differentiated Thyroid Carcinoma. <i>Thyroid</i> , 2015, 25, 300-307.	2.4	121
141	Response to Initial Therapy Predicts Clinical Outcomes in Medullary Thyroid Cancer. <i>Thyroid</i> , 2015, 25, 242-249.	2.4	73
142	Association Between <i>BRAF</i> V600E Mutation and Recurrence of Papillary Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 42-50.	0.8	448
143	Preoperative Neck Ultrasound in Clinical Node-Negative Differentiated Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3686-3693.	1.8	16
144	Prognostic Factors in Papillary Microcarcinoma with Emphasis on Histologic Subtyping: A Clinicopathologic Study of 148 Cases. <i>Thyroid</i> , 2014, 24, 245-253.	2.4	51

#	ARTICLE	IF	CITATIONS
145	Comparable outcomes for patients with pT1a and pT1b differentiated thyroid cancer: Is there a need for change in the AJCC classification system?. <i>Surgery</i> , 2014, 156, 1484-1490.	1.0	23
146	Oncologic Outcomes After Completion Thyroidectomy for Patients with Well-Differentiated Thyroid Carcinoma. <i>Annals of Surgical Oncology</i> , 2014, 21, 1374-1378.	0.7	38
147	Optimal management of a biochemical incomplete response to therapy in differentiated thyroid cancer: aggressive treatment or cautious observation?. <i>Endocrine</i> , 2014, 46, 363-364.	1.1	15
148	Higher Administered Activities of Radioactive Iodine Are Associated with Less Structural Persistent Response in Older, but Not Younger, Papillary Thyroid Cancer Patients with Lateral Neck Lymph Node Metastases. <i>Thyroid</i> , 2014, 24, 1088-1095.	2.4	45
149	The impact of nodal status on outcome in older patients with papillary thyroid cancer. <i>Surgery</i> , 2014, 156, 137-146.	1.0	98
150	Update on Differentiated Thyroid Cancer Staging. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014, 43, 401-421.	1.2	157
151	Thyroid Carcinoma, Version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1671-1680.	2.3	147
152	Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 1493.	3.8	775
153	Outcomes of Patients with Differentiated Thyroid Cancer Risk-Stratified According to the American Thyroid Association and Latin American Thyroid Society Risk of Recurrence Classification Systems. <i>Thyroid</i> , 2013, 23, 1401-1407.	2.4	138
154	American Thyroid Association Statement on Outpatient Thyroidectomy. <i>Thyroid</i> , 2013, 23, 1193-1202.	2.4	229
155	Risk stratification in medullary thyroid cancer: Moving beyond static anatomic staging. <i>Oral Oncology</i> , 2013, 49, 695-701.	0.8	35
156	Prophylactic Central Neck Dissection in Differentiated Thyroid Cancer: An Assessment of the Evidence. <i>Annals of Surgical Oncology</i> , 2013, 20, 2285-2289.	0.7	61
157	Selective use of RAI for ablation and adjuvant therapy after total thyroidectomy for differentiated thyroid cancer: A practical approach to clinical decision making. <i>Oral Oncology</i> , 2013, 49, 676-683.	0.8	37
158	Thyroid Lobectomy Is Associated with Excellent Clinical Outcomes in Properly Selected Differentiated Thyroid Cancer Patients with Primary Tumors Greater Than 1â€‰cm. <i>Journal of Thyroid Research</i> , 2013, 1-5.	0.5	52
159	A Low Postoperative Nonstimulated Serum Thyroglobulin Level Does Not Exclude the Presence of Radioactive Iodine Avid Metastatic Foci in Intermediate-Risk Differentiated Thyroid Cancer Patients. <i>Thyroid</i> , 2013, 23, 436-442.	2.4	58
160	Recombinant Human Thyroid-Stimulating Hormone To Stimulate 131-I Uptake For Remnant Ablation And Adjuvant Therapy. <i>Endocrine Practice</i> , 2013, 19, 149-156.	1.1	9
161	Recombinant Human Thyroid Stimulating Hormoneâ€“Assisted Radioactive Iodine Remnant Ablation in Thyroid Cancer Patients at Intermediate to High Risk of Recurrence. <i>Thyroid</i> , 2012, 22, 1007-1015.	2.4	70
162	Papillary Thyroid Carcinomas with Cervical Lymph Node Metastases Can Be Stratified into Clinically Relevant Prognostic Categories Using Oncogenic <i>BRAF</i> , the Number of Nodal Metastases, and Extra-Nodal Extension. <i>Thyroid</i> , 2012, 22, 575-584.	2.4	108

#	ARTICLE	IF	CITATIONS
163	Even Without Additional Therapy, Serum Thyroglobulin Concentrations Often Decline for Years After Total Thyroidectomy and Radioactive Remnant Ablation in Patients with Differentiated Thyroid Cancer. <i>Thyroid</i> , 2012, 22, 778-783.	2.4	77
164	The Prognostic Significance of Nodal Metastases from Papillary Thyroid Carcinoma Can Be Stratified Based on the Size and Number of Metastatic Lymph Nodes, as Well as the Presence of Extranodal Extension. <i>Thyroid</i> , 2012, 22, 1144-1152.	2.4	647
165	American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. <i>Thyroid</i> , 2012, 22, 1104-1139.	2.4	717
166	Changing trends in well differentiated thyroid carcinoma over eight decades. <i>International Journal of Surgery</i> , 2012, 10, 618-623.	1.1	33
167	American Thyroid Association Statement on the Essential Elements of Interdisciplinary Communication of Perioperative Information for Patients Undergoing Thyroid Cancer Surgery. <i>Thyroid</i> , 2012, 22, 395-399.	2.4	67
168	Clinical Outcomes Following Empiric Radioiodine Therapy in Patients with Structurally Identifiable Metastatic Follicular Cell-Derived Thyroid Carcinoma with Negative Diagnostic But Positive Post-Therapy ¹³¹ I Whole-Body Scans. <i>Thyroid</i> , 2012, 22, 877-883.	2.4	53
169	American Thyroid Association Design and Feasibility of a Prospective Randomized Controlled Trial of Prophylactic Central Lymph Node Dissection for Papillary Thyroid Carcinoma. <i>Thyroid</i> , 2012, 22, 237-244.	2.4	200
170	Role of Recombinant Human Thyrotropin (rhTSH) in the Treatment of Well-Differentiated Thyroid Cancer. <i>Indian Journal of Surgical Oncology</i> , 2012, 3, 182-189.	0.3	6
171	Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. <i>Clinical Endocrinology</i> , 2012, 77, 132-138.	1.2	226
172	Ultrasonographically Detected Small Thyroid Bed Nodules Identified After Total Thyroidectomy for Differentiated Thyroid Cancer Seldom Show Clinically Significant Structural Progression. <i>Thyroid</i> , 2011, 21, 845-853.	2.4	113
173	Clinical Relevance of Thyroglobulin Doubling Time in the Management of Patients with Differentiated Thyroid Cancer. <i>Thyroid</i> , 2011, 21, 691-692.	2.4	27
174	Similarities and Differences in Follicular Cell-Derived Thyroid Cancer Management Guidelines Used in Europe and the United States. <i>Seminars in Nuclear Medicine</i> , 2011, 41, 89-95.	2.5	11
175	A Risk-Adapted Approach to the Use of Radioactive Iodine and External Beam Radiation in the Treatment of Well-Differentiated Thyroid Cancer. <i>Cancer Control</i> , 2011, 18, 89-95.	0.7	35
176	Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer. <i>Clinical Endocrinology</i> , 2011, 75, 112-119.	1.2	164
177	Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. <i>Cancer</i> , 2011, 117, 4439-4446.	2.0	265
178	In Differentiated Thyroid Cancer, an Incomplete Structural Response to Therapy Is Associated with Significantly Worse Clinical Outcomes Than Only an Incomplete Thyroglobulin Response. <i>Thyroid</i> , 2011, 21, 1317-1322.	2.4	116
179	Radioactive Iodine Administered for Thyroid Remnant Ablation Following Recombinant Human Thyroid Stimulating Hormone Preparation Also Has an Important Adjuvant Therapy Function. <i>Thyroid</i> , 2010, 20, 257-263.	2.4	60
180	Estimating Risk of Recurrence in Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation: Using Response to Therapy Variables to Modify the Initial Risk Estimates Predicted by the New American Thyroid Association Staging System. <i>Thyroid</i> , 2010, 20, 1341-1349.	2.4	785

#	ARTICLE	IF	CITATIONS
181	The Effect of Posttherapy ¹³¹ I SPECT/CT on Risk Classification and Management of Patients with Differentiated Thyroid Cancer. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1361-1367.	2.8	102
182	Mild Decreases in White Blood Cell and Platelet Counts Are Present One Year After Radioactive Iodine Remnant Ablation. <i>Thyroid</i> , 2009, 19, 1035-1041.	2.4	41
183	Salivary Gland Side Effects Commonly Develop Several Weeks After Initial Radioactive Iodine Ablation. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1605-1610.	2.8	106
184	Mutational Profile of Advanced Primary and Metastatic Radioactive Iodine-Refractory Thyroid Cancers Reveals Distinct Pathogenetic Roles for <i>BRAF</i> , <i>PIK3CA</i> , and <i>AKT1</i> . <i>Cancer Research</i> , 2009, 69, 4885-4893.	0.4	488
185	Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. <i>Thyroid</i> , 2009, 19, 1167-1214.	2.4	6,039
186	Encapsulated Papillary Thyroid Carcinoma: A Clinico-Pathologic Study of 106 Cases with Emphasis on Its Morphologic Subtypes (Histologic Growth Pattern). <i>Thyroid</i> , 2009, 19, 119-127.	2.4	125
187	Postoperative Management of Well-Differentiated Thyroid Cancer. , 2009, , 137-148.		0
188	Can risk-adapted treatment recommendations replace the 'one size fits all' approach for early-stage thyroid cancer patients?. <i>Oncology</i> , 2009, 23, 592, 600, 603.	0.4	2
189	Medical management of thyroid cancer: a risk adapted approach. <i>Journal of Surgical Oncology</i> , 2008, 97, 712-716.	0.8	57
190	Follow up Approaches in Thyroid Cancer: A Risk Adapted Paradigm. <i>Endocrinology and Metabolism Clinics of North America</i> , 2008, 37, 419-435.	1.2	100
191	ret/PTC Activation Is Not Associated with Individual Radiation Dose Estimates in a Pilot Study of Neoplastic Thyroid Nodules Arising in Russian Children and Adults Exposed to Chernobyl Fallout. <i>Thyroid</i> , 2008, 18, 839-846.	2.4	24
192	Recombinant Human TSH-Assisted Radioactive Iodine Remnant Ablation Achieves Short-Term Clinical Recurrence Rates Similar to Those of Traditional Thyroid Hormone Withdrawal. <i>Journal of Nuclear Medicine</i> , 2008, 49, 764-770.	2.8	143
193	Risk-Adapted Management of Thyroid Cancer. <i>Endocrine Practice</i> , 2008, 14, 764-774.	1.1	77
194	Radioactive iodine therapy in poorly differentiated thyroid cancer. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 665-668.	4.3	17
195	Impact of Pregnancy on Serum Thyroglobulin and Detection of Recurrent Disease Shortly After Delivery in Thyroid Cancer Survivors. <i>Thyroid</i> , 2007, 17, 543-547.	2.4	54
196	Investigational Therapies for Metastatic Thyroid Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007, 5, 641-646.	2.3	16
197	Papillary Thyroid Cancer: Monitoring and Therapy. <i>Endocrinology and Metabolism Clinics of North America</i> , 2007, 36, 753-778.	1.2	67
198	Treatment of Thyroid Cancer: 2007 A Basic Review. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S92-S97.	0.4	18

#	ARTICLE	IF	CITATIONS
199	Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Taskforce. <i>Thyroid</i> , 2006, 16, 109-142.	2.4	1,857
200	Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis. <i>Cancer</i> , 2006, 106, 1286-1295.	2.0	266
201	Follicular variant of papillary thyroid carcinoma. <i>Cancer</i> , 2006, 107, 1255-1264.	2.0	363
202	Real-Time Prognosis for Metastatic Thyroid Carcinoma Based on 2-[18F]Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography Scanning. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 498-505.	1.8	513
203	Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. <i>Journal of Nuclear Medicine</i> , 2006, 47, 1587-91.	2.8	127
204	Ret/PTC Activation in Benign and Malignant Thyroid Tumors Arising in a Population Exposed to Low-Dose External-Beam Irradiation in Childhood. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 2281-2289.	1.8	44
205	Factors Influencing the Basal and Recombinant Human Thyrotropin-Stimulated Serum Thyroglobulin in Patients with Metastatic Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 6010-6016.	1.8	72
206	Is the Serum Thyroglobulin Response to Recombinant Human Thyrotropin Sufficient, by Itself, to Monitor for Residual Thyroid Carcinoma?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 3242-3247.	1.8	134
207	Differentiated Thyroid Carcinoma That Express Sodium-Iodide Symporter Have a Lower Risk of Recurrence for Children and Adolescents. <i>Pediatric Research</i> , 2002, 52, 737-744.	1.1	7
208	A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. <i>Journal of Nuclear Medicine</i> , 2002, 43, 1482-8.	2.8	95
209	Expression of the Sodium Iodide Symporter and Thyroglobulin Genes Are Reduced in Papillary Thyroid Cancer. <i>Modern Pathology</i> , 2001, 14, 289-296.	2.9	91
210	Resistance of [18F]-Fluorodeoxyglucose-Avid Metastatic Thyroid Cancer Lesions to Treatment with High-Dose Radioactive Iodine. <i>Thyroid</i> , 2001, 11, 1169-1175.	2.4	172
211	The Chernobyl accident and its consequences: Update at the millennium. <i>Seminars in Nuclear Medicine</i> , 2000, 30, 133-140.	2.5	134
212	Theret/PTC Mutations Are Common in Sporadic Papillary Thyroid Carcinoma of Children and Young Adults1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 1170-1175.	1.8	201
213	The Prognostic Significance of Nodal Metastases from Papillary Thyroid Carcinoma can be Stratified Based on the Size and Number of Metastatic Lymph Nodes, as Well as the Presence of Extranodal Extension ATA Surgical Affairs Committee's Taskforce on Thyroid Cancer Nodal Surgery. <i>Thyroid</i> , 0, , 120810100637005.	2.4	14